spacer
home > pmps > autumn 2017 > what now?
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

What Now?

With the recent FDA announcement regarding a one-year delay in enforcement of the compliance policy for ‘Product Identified Requirements Under the Drug Supply Chain Security Act’ (DSCSA), many are left asking what this actually means for the wider pharmaceutical industry or their company’s initiatives. While the FDA communication specifically indicates a delay in enforcement, it is clear there is no delay of the law itself – a telling signal to the industry that this serialisation challenge is real.

Within the industry, much speculation and scepticism exists regarding what will happen in November 2017. Given the history of deadlines coming and going in California for most of a decade, followed by a national mandate passed by the US Congress (albeit watered down), many in the industry were left dubious that the government could realistically enforce the deadline. Furthermore, regulations and administration in Europe, Brazil and China have been walked back, morphed or changed over the past 12-18 months, adding to the industry’s doubts.

Over the past three to six months, the drumbeat of industry representatives appealing to the FDA for delayed enforcement has steadily increased. Despite best efforts, the industry as a whole is not prepared, and will not be so, for November of this year. While many leading pharma companies have actively progressed their serialisation initiatives, a large portion dragged their heels in a wait-and-see approach to enforcement. Equipment suppliers, third-party electronic product code information services providers, consultants and contract manufacturing organisations have raised concerns over the anticipated skyrocketing demand on resources as we approach the deadline. Since the beginning of 2017, those concerns have been fully realised. The industry simply does not have the collective resources to enable every pharma company to comply. Fortunately, the FDA listened to their concerns and acted accordingly. The industry has been given a reprieve – some breathing room – to get through the collective implementation. In the scope of work required for serialisation implementation, an additional 12 months is not a lot of time. It would be a very poor decision for any company to delay their current activity with the thought that the goal line has moved significantly.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Justin Schroeder is Senior Executive Director of Global Marketing and Design at PCI Pharma Services. He is responsible for global marketing, creative package design and new account development, with a focus on the development and commercialisation of new products. Justin has over 20 years of experience in outsourced pharma services in various roles, including engineering, project management, marketing and development. He holds a Bachelor of Science from the School of Packaging at Michigan State University, US, and an MBA in marketing from Northern Illinois University, US. Justin is a certified Packaging Professional from the Institute of Packaging Professionals, US, and is the Vice Chairman of the US Healthcare Compliance Packaging Council. 
spacer
Justin Schroeder
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

PPMA Group Industry Awards 2018 Call for Entries – Deadline 31st July

The PPMA Group Industry Awards, which recognise manufacturing excellence, technical innovation, entrepreneurship as well as outstanding achievement and contribution to the industry, will this year take place at a new venue – the Hilton Birmingham Metropole Hotel at the NEC - on the 25th September 2018.
More info >>

White Papers

BioT ULT Transporter

BioCision

The growth of biobanking, cell therapy, and complex biopharmaceutical therapies like cancer vaccines has created a strong need for products and processes to ensure the stability of temperature­-sensitive biospecimens. Proper collection, handling, characterization, packaging and shipping of these materials is critical, as poor sample handling impacts researchers working on discovery with patient samples, as well as clinicians treating patients with cutting edge therapies. This white paper describes in detail the BioCision BioT™ ULT Transporter, the first-of-its-kind dry ice-based portable cooling system that maintains a stable -75° to -50°C environment for over 24 hours on one charge of dry ice, enabling reliable handling and transfer of valuable temperature-sensitive biospecimens as part of a larger cold chain standardization process.
More info >>

 
Industry Events

Nordic Life Science Days 2018

10-12 September 2018, Stockholm Waterfront Conference Center, Sweden

The Nordic way of doing life science business NLSDays offers networking and knowledge for anyone interested in the Nordic life science, biotechnologies, pharmaceuticals, medical devices and e-health business. We offer plenty of opportunities to connect.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement